These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37940048)

  • 21. Peri-operative hemostatic management of tooth extraction in patients with hemophilia A, with and without inhibitors, receiving emicizumab prophylaxis.
    Yagyuu T; Furukawa S; Zaizen M; Yata S; Imada M; Nogami K; Kirita T
    Haemophilia; 2023 Jan; 29(1):172-179. PubMed ID: 36163647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emicizumab, A Bispecific Antibody to Factors IX/IXa and X/Xa, Does Not Interfere with Antithrombin or TFPI Activity In Vitro.
    Noguchi-Sasaki M; Soeda T; Ueyama A; Muto A; Hirata M; Kitamura H; Fujimoto-Ouchi K; Kawabe Y; Nogami K; Shima M; Kitazawa T
    TH Open; 2018 Jan; 2(1):e96-e103. PubMed ID: 31249933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced plasma factor X is associated with a lack of response to recombinant activated factor VII in patients with hemophilia A and inhibitor, but does not impair emicizumab-driven hemostasis in vitro.
    Yada K; Fujitate N; Ogiwara K; Soeda T; Kitazawa T; Nogami K
    Thromb Res; 2024 May; 237():37-45. PubMed ID: 38547693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice.
    Østergaard H; Lund J; Greisen PJ; Kjellev S; Henriksen A; Lorenzen N; Johansson E; Røder G; Rasch MG; Johnsen LB; Egebjerg T; Lund S; Rahbek-Nielsen H; Gandhi PS; Lamberth K; Loftager M; Andersen LM; Bonde AC; Stavenuiter F; Madsen DE; Li X; Holm TL; Ley CD; Thygesen P; Zhu H; Zhou R; Thorn K; Yang Z; Hermit MB; Bjelke JR; Hansen BG; Hilden I
    Blood; 2021 Oct; 138(14):1258-1268. PubMed ID: 34077951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients.
    Nakajima Y; Mizumachi K; Shimonishi N; Furukawa S; Yada K; Ogiwara K; Takeyama M; Shima M; Nogami K
    Int J Hematol; 2022 Apr; 115(4):489-498. PubMed ID: 35043383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab.
    Nogami K; Matsumoto T; Tabuchi Y; Soeda T; Arai N; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jun; 16(6):1078-1088. PubMed ID: 29645406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical pharmacology of emicizumab for the treatment of hemophilia A.
    Yoneyama K; Schmitt C; Portron A; Kiialainen A; Kotani N; Jaminion F; Retout S; Adamkewicz JI
    Expert Rev Clin Pharmacol; 2023; 16(9):775-790. PubMed ID: 37529848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort.
    Barg AA; Avishai E; Budnik I; Levy-Mendelovich S; Barazani TB; Kenet G; Livnat T
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27886. PubMed ID: 31348595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro validation of chromogenic substrate assay for evaluation of surrogate FVIII-activity of emicizumab.
    Yamaguchi T; Shinozawa K; Nagatoishi S; Mitsuhashi A; Bingo M; Inaba H; Amano K; Tsumoto K; Kinai E
    Thromb Res; 2023 Feb; 222():131-139. PubMed ID: 36657269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity.
    Kitazawa T; Shima M
    Int J Hematol; 2020 Jan; 111(1):20-30. PubMed ID: 30350119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A bispecific antibody mimicking factor VIII in hemophilia A therapy].
    Nogami K
    Rinsho Ketsueki; 2016 Jun; 57(6):709-14. PubMed ID: 27384849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The combination of emicizumab and recombinant factor VIII in plasma: Which assays can we use for accurate measurement?
    Bowyer AE; Maclean RM; Kitchen S
    Int J Lab Hematol; 2023 Jun; 45(3):368-376. PubMed ID: 36710421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy/effectiveness and safety of emicizumab prophylaxis of people with hemophilia A: a systematic review and meta-analysis.
    Muniz RL; Camelo RM; Araújo MS; Barbosa MM; Guerra AA; Acurcio FA; Alvares-Teodoro J
    Expert Rev Hematol; 2023; 16(12):1087-1097. PubMed ID: 38066708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early real-world experience with emicizumab and concomitant factor VIII replacement products in adult males with Hemophilia A without inhibitors.
    Cafuir L; Estrin A; Chen E; Hinds D; Prince P; Thorburn J; Mead H; Kempton CL
    J Med Econ; 2022; 25(1):984-992. PubMed ID: 35848992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma.
    Tripodi A; Chantarangkul V; Novembrino C; Scalambrino E; Boscolo-Anzoletti M; Clerici M; Rossi F; Peyvandi F
    Clin Chem Lab Med; 2020 Sep; 59(2):365-371. PubMed ID: 32892172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The in vitro effect of anticoagulant agents on coagulation and fibrinolysis in the presence of emicizumab in the plasmas from patients with haemophilia A.
    Onishi T; Harada S; Shimo H; Tashiro Y; Soeda T; Nogami K
    Haemophilia; 2023 Nov; 29(6):1529-1538. PubMed ID: 37766492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
    Bowyer A; Kitchen S; Maclean R
    Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays.
    Adamkewicz JI; Chen DC; Paz-Priel I
    Thromb Haemost; 2019 Jul; 119(7):1084-1093. PubMed ID: 31064025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emicizumab for the treatment of acquired hemophilia A.
    Knoebl P; Thaler J; Jilma P; Quehenberger P; Gleixner K; Sperr WR
    Blood; 2021 Jan; 137(3):410-419. PubMed ID: 32766881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A hemophilia A mouse model for the in vivo assessment of emicizumab function.
    Ferrière S; Peyron I; Christophe OD; Kawecki C; Casari C; Muczynski V; Nathwani A; Kauskot A; Lenting PJ; Denis CV
    Blood; 2020 Aug; 136(6):740-748. PubMed ID: 32369559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.